Short answer
Theravance Biopharma, Inc. (TBPH) filed an 8-K current report with the SEC on May 7, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Exhibit 99.1 furnished under Item 2.02, containing the company’s fiscal-year 2026 results.
Theravance Biopharma, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Exhibit 99.1 furnished under Item 2.02, containing the company’s fiscal-year 2026 results
- Information not deemed filed under Exchange Act Section 18, limiting associated liability
- Exhibit not incorporated by reference into other filings unless expressly referenced
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Theravance Biopharma, Inc. 8-K filings
Get the next TBPH 8-K as it lands
Follow TBPH for push alerts, or ask the research agent what this filing means.